SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/334788"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/334788" > One-Third of Europe...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005395naa a2200793 4500
001oai:gup.ub.gu.se/334788
003SwePub
008240528s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:236455943
009oai:prod.swepub.kib.ki.se:154883483
0247 a https://gup.ub.gu.se/publication/3347882 URI
0247 a https://doi.org/10.3899/jrheum.2204592 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2364559432 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1548834832 URI
040 a (SwePub)gud (SwePub)kid (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ornbjerg, Lykke Midtboll4 aut
2451 0a One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
264 c 2022-12-01
264 1b The Journal of Rheumatology,c 2023
520 a Objective. To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor ( TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the modified New York (mNY) criteria for ankylosing spondylitis (AS) vs patients with nonradiographic axSpA (nr-axSpA). Methods. Fifteen European registries contributed PRO scores for pain, fatigue, patient global assessment (PtGA), Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Health Assessment Questionnaire (HAQ) from 19,498 patients with axSpA. Changes in PROs and PRO remission rates (definitions: <= 20 mm for pain, fatigue, PtGA, BASDAI, and BASFI; <= 0.5 for HAQ) were calculated at 6, 12, and 24 months of treatment. Results. Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, 6 months after the start of a first TNFi, pain score was reduced by approximately 60% (median at baseline/6/12/24 months: 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25 mm), PtGA (66/29/21/20 mm), BASDAI (58/26/21/19 mm), BASFI (46/20/16/16 mm), and HAQ (0.8/0.4/0.2/0.2). Patients with AS (n = 3281) had a slightly better response than patients with nr-axSpA (n = 993). The Lund Efficacy Index (LUNDEX)-adjusted remission rates at 6 months for pain/fatigue/PtGA/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the nr-axSpA cohort. Better PRO responses were seen with a first TNFi compared to a second and third TNFi. Conclusion. Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a axial spondyloarthritis
653 a patient-reported outcome measures
653 a tumor necrosis factor inhibitors
7001 a Rugbjerg, Kathrine4 aut
7001 a Georgiadis, Stylianos4 aut
7001 a Rasmussen, Simon Horskjaer4 aut
7001 a Lindström, Ulfu Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xlulfn
7001 a Pavelka, Karel4 aut
7001 a Yilmaz, Neslihan4 aut
7001 a Favalli, Ennio Giulio4 aut
7001 a Nissen, Michael J.4 aut
7001 a Michelsen, Brigitte4 aut
7001 a Vieira-Sousa, Elsa4 aut
7001 a Jones, Gareth T.4 aut
7001 a Ionescu, Ruxandra4 aut
7001 a Relas, Heikki4 aut
7001 a Sanchez-Piedra, Carlos4 aut
7001 a Tomsic, Matija4 aut
7001 a Geirsson, Arni Jon4 aut
7001 a van der Horst-Bruinsma, Irene4 aut
7001 a Askling, Johanu Karolinska Institutet4 aut
7001 a Loft, Anne Gitte4 aut
7001 a Nekvindova, Lucie4 aut
7001 a Direskeneli, Haner4 aut
7001 a Iannone, Florenzo4 aut
7001 a Ciurea, Adrian4 aut
7001 a Fagerli, Karen Minde4 aut
7001 a Santos, Maria Jose4 aut
7001 a Macfarlane, Gary J.4 aut
7001 a Codreanu, Catalin4 aut
7001 a Eklund, Kari4 aut
7001 a Pombo-Suarez, Manuel4 aut
7001 a Rotar, Ziga4 aut
7001 a Gudbjornsson, Bjorn4 aut
7001 a Rusman, Tamara4 aut
7001 a Ostergaard, Mikkel4 aut
7001 a Hetland, Merete Lund4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning4 org
7730 t JOURNAL OF RHEUMATOLOGYd : The Journal of Rheumatologyg 50:8, s. 1009-1019q 50:8<1009-1019x 0315-162Xx 1499-2752
8564 8u https://gup.ub.gu.se/publication/334788
8564 8u https://doi.org/10.3899/jrheum.220459
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:236455943
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154883483

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy